A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma

Phase 2

Terminated

Conditions: Asthma

Interventions: Biological: MEDI528 50 mg
Other: PLACEBO

Registration Number: NCT00590720

Lead Sponsor: MedImmune LLC

Brief Summary: The main objective of this study is to evaluate the safety and tolerability of multiple fixed doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction (EIB).

Detailed Description: The primary objective of this study is to evaluate the safety and tolerability of multiple fixed escalating SC doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction (EIB).

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 11

Inclusion Criteria

Patients must meet all of the following criteria:

Male or female adults, age 18 through 50 years at the time of screening;
Weight 50-100 kg and body mass index ≤ 35;
Written informed consent obtained from the patient prior to receipt of any study medication or beginning study procedures;
Documented clinical history of asthma and receiving stable treatment for ≥ 1 month prior to Study Day 0;
Airway hyperresponsiveness (AHR) on methacholine inhalation challenge testing at screening (or a documented history within the past 6 months), with provoking concentration of methacholine to cause a 20% fall in FEV1(subscript) (PC20) ≤ 8 mg/mL (Crapo, 2000);
Exercise-induced bronchoconstriction (EIB) with a decrease in FEV1 (subscript) of ≥ 15% from pre-exercise challenge testing level at screening;
Able to provide spirometry readings that meet American Thoracic Society (ATS) and European Respiratory Society (ERS) standards (Miller, 2005);
Women of childbearing potential, unless surgically sterile or at least 1 year post-menopausal, must use two effective methods of avoiding pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine device, female condom, spermicide, diaphragm, cervical cap, abstinence, contraceptive foam, or use of a condom by the sexual partner or sterile sexual partner) from screening through Study Day 0, and must agree to continue using such precautions through Study Day 150. Cessation of birth control after this point should be discussed with a responsible physician. Men, unless surgically sterile, must likewise use an effective method of birth control (condom with spermicide) and must agree to continue using such precautions from screening through Study Day 150;
Able to complete the study period, including follow-up period, of up to approximately 150 days; and
Willing to forego other forms of experimental treatment and study procedures during the study and for 30 days after the follow-up period is completed.

Exclusion Criteria

Patients must have none of the following criteria:

Receipt of MEDI-528 in any previous clinical study;
History of allergy or reaction to any component of the study drug formulation;
Lung disease other than asthma (eg, chronic obstructive pulmonary disease, cystic fibrosis);
Forced expiratory volume in 1 second (FEV1-subscript) < 70% of predicted values at screening;
Use of systemic immunosuppressive drugs including systemic corticosteroids, ICS with doses > 800 μg/day budesonide (or another ICS of equivalent dose), long-acting β2 agonists, cromolyn sodium, nedocromil sodium, leukotriene receptor antagonists, theophylline, or omalizumab from screening through Study Day 150;
Current use of any β-adrenergic antagonist (eg, propranolol);
Any disease or illness, other than asthma, that is likely to require the use of systemic corticosteroids during the study period;
Acute illnesses or evidence of significant active infection, such as fever ≥ 38.0°C (100.5°F) from screening through Study Day 0;
Current allergy vaccination therapy (desensitization immunotherapy);
Receipt of any investigational drug therapy within 30 days or any biologic(s) within 5 half-lives of the agent prior to screening;
Pregnancy (women of child bearing potential, unless surgically sterile or at least 1 year postmenopausal, must have a negative serum and urine pregnancy test at screening before methacholine inhalation challenge testing and a negative urine pregnancy test prior to study drug administration on Study Day 0);
Breastfeeding or lactating woman;
Evidence of infection with hepatitis B or C virus or HIV-1 or HIV-2, or active infection with hepatitis A; must have negative HIV-1, HIV-2, hepatitis A, B, and C tests at screening;
History of cancer other than basal cell carcinoma of the skin or cervical carcinoma-in-situ treated with apparent success with curative therapy more than 1 year prior to Study Day 0;
History of primary immunodeficiency
History of pancreatitis or currently active gastroduodenal ulcer;
Current use of tobacco products or a history of use of tobacco products of more than one cigarette per month or equivalent within 1 year prior to randomization or history of smoking of ≥ 10 pack-years;
History of life-long urinary retention;
History of anaphylaxis (defined as immediate life-threatening event requiring medical invention);
Elective surgery planned from screening through Study Day 150;
Clinically significant abnormality, as determined by the investigator, on 12-lead ECG or chest radiograph at screening;
History of any disease, evidence of any current disease (other than asthma), any finding upon physical examination, or any laboratory abnormality, that, in the opinion of the investigator or medical monitor, may compromise the safety of the patient in the study or confound the analysis of the study; or
Any employee of the research site who is involved with the conduct of the study.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
MEDI528 50 mg	MEDI528 50 mg	MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
PLACEBO	PLACEBO	Placebo administered as a subcutaneous injection twice weekly for 4 weeks

Primary Outcome Measures

Name	Time	Method
Incidence of Adverse Events	Days 0 - 150	Number of participants experiencing adverse events (includes both adverse events and serious adverse events)
Incidence of Serious Adverse Events	Days 0 - 150	Number of participants experiencing serious adverse events

Secondary Outcome Measures

Name	Time	Method
Incidence of Anti-drug Antibodies (ADA) to MEDI-528	Days 0, 28, 56, 119, and 150	Number of participants with ADA to MEDI-528
Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)	Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the maximum change in FEV1 before and after exercise on Day 150.
Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)	Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the percent maximum change in FEV1 before and after exercise on Day 150.
Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)	Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	AUC of FEV1 at Day 150
Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)	Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	Time to return in minutes to 90 percent of baseline FEV1 (prior to exercise) after exercise on Day 150
Mean Trough Concentration (Cmin)	Days 0, 3, 7, 10, 14, 17, 21, 24, 28, 32, 37, 42, 56, 70, 84, 119, and 150	Cmin of MEDI-528
Mean Trough Concentration at Last Measurable Time Point (Cmin_last)	Days 0, 3, 7, 10, 14, 17, 21, 24, 28, 32, 37, 42, 56, 70, 84, 119, and 150	Cmin_last of MEDI-528
Half-life (T1/2)	Days 0, 3, 7, 10, 14, 17, 21, 24, 28, 32, 37, 42, 56, 70, 84, 119, and 150	T1/2 of MEDI-528
Accumulation Index	Days 0 and 24	Ratio of trough concentrations after first (Day 0) and last (Day 24) dose of MEDI-528

Trial Locations

Locations (12): UHN- Toronto Western Hospital
🇨🇦
Toronto, Ontario, Canada
Northeast Medical Research Associates, Inc
🇺🇸
No. Dartmouth, Massachusetts, United States
Institute of Healthcare Assessment, Inc
🇺🇸
San Diego, California, United States
The Clinical Research Center, LLC
🇺🇸
St. Louis, Missouri, United States
National Jewish Medical and Research Center
🇺🇸
Denver, Colorado, United States
Waterbury Pulmonary Associates
🇺🇸
Waterbury, Connecticut, United States
Centre de Recherche Appliquee en Allergie de Quebec
🇨🇦
Quebec City, Quebec, Canada
Sneeze,Wheeze & Itch Associates, LLC
🇺🇸
Normal, Illinois, United States
Calgary COPD & Asthma Program
🇨🇦
Calgary, Alberta, Canada
Bernstein Clinical Research Center
🇺🇸
Cincinnati, Ohio, United States
Creighton University
🇺🇸
Omaha, Nebraska, United States
Univ. of South Florida, Asthma, Allergy & Immunology Clinical Research Unit
🇺🇸
Tampa, Florida, United States